Sector News

Ipsen signs option to buy UCL spin-out Canbex

February 24, 2015
Life sciences
France’s Ipsen has bought an option to acquire the UK’s Canbex Therapeutics, which is working on a treatment for spasticity in people with multiple sclerosis.
 
Canbex is a spin-off of University College London that raised £2.3 million in 2013 from MS Ventures (the corporate venture arm of Merck KGaA), the Wellcome Trust and UCL Business. The therapy in question, called VSN16R, which has been shown in preclinical and Phase I studies to have the potential to provide substantially better patient care than existing systemic anti-spastic treatments, Ipsen says.
 
Ipsen has paid 6 million euros for the option to acquire Canbex at completion of a Phase IIa study. The latter’s present shareholders will be eligible to receive up to an additional 90 million euros, comprising an acquisition payment, plus royalties on VSN16R.
 
Ipsen chief executive Marc de Garidel said Canbex’ lead compound “has demonstrated excellent safety, efficacy and tolerability to date and fits well within our neurology franchise”. He added that “it could be a valuable companion product” to his company’s wrinkles and cervical dystonia treatment Dysport (abobotulinumtoxin A) in the treatment of spasticity.
 
By Kevin Grogan
 
Source: Pharma Times

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend